Defective mutant non-retroviral virus (e.g. hsv) as vaccine

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/245 (2006.01) C07K 14/035 (2006.01) C12N 7/04 (2006.01) C12N 15/86 (2006.01) C12N 15/869 (2006.01) A61K 38/00 (2006.01) A61K 39/00 (2006.01)

Patent

CA 2158148

The application provides a pharmaceutical which comprises a mutant non-retroviral virus (particularly HSV-1 and/or HSV-2) whose genome is defective in respect of a gene essential for the production of infectious virus. The virus can infect normal cells and undergo replication and expression of viral antigen genes in those cells but cannot produce normal infectious virus. The pharmaceutical is for prophylactic or therapeutic use in generating an immune response in a subject infected therewith. Where the non-retroviral virus is a herpes simplex virus e.g. HSV-1 or HSV-2, the defect can be in the glycoprotein gH gene. Vaccines and therapeutic pharmaceuticals are provided especially for epithelial, oral, vaginal and nasal administration. Also provided is use of a mutant based on HSV-1 for the preparation of a pharmaceutical for prophylactic ore therapeutic use in generating an immune response in a subject against type-2 HSV infection.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Defective mutant non-retroviral virus (e.g. hsv) as vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Defective mutant non-retroviral virus (e.g. hsv) as vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Defective mutant non-retroviral virus (e.g. hsv) as vaccine will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2032243

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.